Specifically, compounds 151 and 152 reduced the tumor volume by triggering apoptosis of both tumor and tumor-associated endothelial cells via inhibition of angiogenesis-related receptor tyrosine kinases including VEGFR2, FGFR1, and EGFR [232,233]. The gene discussed is NTRK1; the disease is neoplasm.